UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 16, 2006
MICROMET, INC.
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
| Delaware
|
|
0-50440
|
|
52-2243564 |
| (State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer |
| of Incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
| 2110 Rutherford Road, Carlsbad, CA
|
|
92008 |
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (760) 494-4200
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
INFORMATION TO BE INCLUDED IN THE REPORT
In accordance with General Instruction B.2. of Form 8-K, the information presented in this
filing and furnished in the exhibits attached hereto shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, except as expressly set
forth by specific reference in such a filing.
Section 7 — Regulation FD
Item 7.01. Regulation FD Disclosure.
On
June 16, 2006, Micromet, Inc. (the “Company”) presented a poster entitled “MT103 (MEDI-538)
Induces B-cell Depletion, Clearance of Bone Marrow Infiltration and Clinical Responses in Heavily
Pre-treated NHL Patients: First Data from Phase I Dose-escalation Study MT103-104” at the 11th
Congress of the European Hematology Association (EHA). The poster is furnished as Exhibit 99.1
hereto, and may also be used in meetings with investors and analysts
and for scientific and industry conferences after the date hereof and
possibly with immaterial modifications. The fact that the poster is being furnished herewith should
not be deemed an admission as to the materiality of any information contained therein. The
information contained in the poster should be considered in the context of our filings with the
Securities and Exchange Commission and other public announcements that we may make, by press
release or otherwise, from time to time.
Additionally, preliminary data from the ongoing phase I trial of MT103 will be presented in an oral
forum presentation to EHA, scheduled for June 17, 2006, by Dr. Ralf Bargou, the principal
investigator of the trial from the University of Wuerzburg, Germany. The powerpoint presentation to
be used in connection with such presentation is furnished as Exhibit 99.2 hereto, and may also be
used in meetings with investors and analysts and for scientific and industry conferences after the date hereof and possibly with immaterial
modifications. The fact that the powerpoint presentation is being furnished herewith should not be
deemed an admission as to the materiality of any information contained therein. The information
contained in the powerpoint presentation should be considered in the context of our filings with
the Securities and Exchange Commission and other public announcements that we may make, by press
release or otherwise, from time to time.
Results from clinical trials, including the preliminary results of the Company’s phase I trial of
MT103, are not necessarily predictive of future clinical results. Preliminary results may not be
confirmed upon full analysis of the detailed results of a trial and additional information relating
to the safety, efficacy or tolerability of the Company’s product candidates, including MT103, may
be discovered upon further analysis of trial data. If the Company’s product candidates do not meet
safety or efficacy endpoints in clinical evaluations, they will not receive regulatory approval and
the Company will not be able to market them. Even if the Company’s product candidates meet safety
and efficacy endpoints, regulatory authorities may not approve them, the Company may not be able to
successfully market them, or the Company may face post-approval problems that require the
withdrawal of its product from the market. There can be no assurance that the Company’s product
candidates, including MT103, will be proven safe and effective for use in humans. The Company’s
results may be affected by its effectiveness at managing its financial resources, its ability to
successfully develop and market its product candidates, competition from other biotechnology and
pharmaceutical companies, difficulties or delays in manufacturing its products, and regulatory
developments involving current and future products. Delays in clinical trials, whether caused by
competition, adverse events, patient enrollment rates, regulatory
issues or other factors, could adversely affect the Company’s financial position and prospects. If
the Company is unable to raise additional capital when required or on acceptable terms, it may have
to significantly delay, scale back or discontinue one or more of its drug development or discovery
research programs. Micromet is at an early stage of development and may not ever have any products
that generate significant revenue.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
99.1
|
|
Poster entitled “MT103 (MEDI-538) Induces B-cell
Depletion, Clearance of Bone Marrow Infiltration and
Clinical Responses in Heavily Pre-treated NHL Patients: First Data from Phase I Dose-escalation Study MT103-104.” |
|
|
|
99.2
|
|
Powerpoint presentation. |